Skip to main content

Table 1 Summary of key input data for Haiti in 2002(All costs in US dollars)

From: Impact of DOTS expansion on tuberculosis related outcomes and costs in Haiti

EPIDEMIOLOGIC/PROGRAMME DATA HAITI REFERENCE/SOURCE  
Population (2002) 8.3 million [9]
Gross National Income annual per capita (US$) $ 440 [9]
Life expectancy at birth 52.0 [9]
All cause mortality Age specific [44]
Incidence new smear positive TB per 100,000 (2001) 138 [8]
Annual risk of TB infection (ARI) 2.26% Calculated from [14] and [8]
Prevalence of LTBI at age 20 41% Calculated from [14]
Likelihood of diagnosis and treatment of LTBI 1% [59] *
Completion of LTBI Treatment 67% [60]
Efficacy of 9 INH – INH Sensitive 90% [61]
INH Resistant 0 [62]
Prevalence of HIV infection – 2002 4.5% [10]
Incidence of HIV infection 0.46%/year Calculated from [35]
DOTS Coverage – 2002 37% [11]
Case detection rate – 2001 49% [8]
Drug Resistance    
   Single drug resistance 20% (11%-31%) [12]
   Multi drug resistance (HR) 0.3% (0–4%) [12;63]
Treatment outcomes New cases – 2001 Overall [8] DOTS areas (NTP) Non-DOTS
   Cure/complete 71% 85% 63%
   Default/transfer/not evaluated 23% 9% 31%
   Die 5% 5% 5%
   Fail 1% 1% 1%
Outcomes Re-treatment cases – 2001 Overall [8] DOTS areas (NTP) Non-DOTS
   Cure/complete 54% 80% 39%
   Default/transfer/not evaluated 29% 4% 44%
   Die 8% 8% 8%
   Fail 8% 8% 8%
  1. Notes:
  2. * – This assumes only dually infected (HIV and TB infection) whose HIV infection is detected and are tuberculin tested at a limited number of screening centres will be treated.
  3. NTP – data on treatment outcomes in areas with DOTS, from cohort reports to National TB programme